Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence

Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2009-02, Vol.112 (2), p.342-347
Hauptverfasser: Fujimoto, Toshio, Nanjyo, Hiroshi, Fukuda, Jun, Nakamura, Akira, Mizunuma, Hideki, Yaegashi, Nobuo, Sugiyama, Toru, Kurachi, Hirohisa, Sato, Akira, Tanaka, Toshinobu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 347
container_issue 2
container_start_page 342
container_title Gynecologic oncology
container_volume 112
creator Fujimoto, Toshio
Nanjyo, Hiroshi
Fukuda, Jun
Nakamura, Akira
Mizunuma, Hideki
Yaegashi, Nobuo
Sugiyama, Toru
Kurachi, Hirohisa
Sato, Akira
Tanaka, Toshinobu
description Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.
doi_str_mv 10.1016/j.ygyno.2008.10.019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66830909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825808008913</els_id><sourcerecordid>66830909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</originalsourceid><addsrcrecordid>eNqFkUGLFDEQhYMo7rj6CwTJyVuPlaSTTgsKy7K6Cwsedj15CJmkes1sT2dM0sL8e9POgOBlTwWP915RXxHylsGaAVMftuvDw2GKaw6gq7IG1j8jKwa9bJSW_XOyAuih0VzqM_Iq5y0ACGD8JTljPSgOmq_Ij6vJxx2WFGLwdC6YwoTU2clh-kivQy5xb8vPOMaH4OxIU8iPdLCuxJRpHOgYF9VOnvrqtVOhCd2cEtaC1-TFYMeMb07znHz_cnV_ed3cfvt6c3lx27i206XhyiuutBPSd952IDV02EkuXC_bTSdAWtV6QOe6oVdeetRWIiBvN63lHRPn5P2xd5_irxlzMbuQHY6jnTDO2SilRSXRV6M4Gl2KOScczD6FnU0Hw8AsTM3W_GVqFqaLWJnW1LtT_bzZof-XOUGshk9HA9YjfwdMJruwAPChwijGx_DEgs__5d0YpgX3Ix4wb-OcpsrPMJO5AXO3vHX5Kuha0jMh_gD6P57-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66830909</pqid></control><display><type>article</type><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</creator><creatorcontrib>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</creatorcontrib><description>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2008.10.019</identifier><identifier>PMID: 19062082</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant chemotherapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Architectural grade ; Carcinoma, Endometrioid - drug therapy ; Carcinoma, Endometrioid - pathology ; Carcinoma, Endometrioid - surgery ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Distant recurrence ; Endometrioid uterine cancer ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Local recurrence ; Lymph Node Excision ; Lymphatic Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics and Gynecology ; Pelvic lymph node metastasis ; Risk Factors ; Uterine Neoplasms - drug therapy ; Uterine Neoplasms - pathology ; Uterine Neoplasms - surgery</subject><ispartof>Gynecologic oncology, 2009-02, Vol.112 (2), p.342-347</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</citedby><cites>FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825808008913$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19062082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujimoto, Toshio</creatorcontrib><creatorcontrib>Nanjyo, Hiroshi</creatorcontrib><creatorcontrib>Fukuda, Jun</creatorcontrib><creatorcontrib>Nakamura, Akira</creatorcontrib><creatorcontrib>Mizunuma, Hideki</creatorcontrib><creatorcontrib>Yaegashi, Nobuo</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Kurachi, Hirohisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Tanaka, Toshinobu</creatorcontrib><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Architectural grade</subject><subject>Carcinoma, Endometrioid - drug therapy</subject><subject>Carcinoma, Endometrioid - pathology</subject><subject>Carcinoma, Endometrioid - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Distant recurrence</subject><subject>Endometrioid uterine cancer</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Local recurrence</subject><subject>Lymph Node Excision</subject><subject>Lymphatic Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Pelvic lymph node metastasis</subject><subject>Risk Factors</subject><subject>Uterine Neoplasms - drug therapy</subject><subject>Uterine Neoplasms - pathology</subject><subject>Uterine Neoplasms - surgery</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUGLFDEQhYMo7rj6CwTJyVuPlaSTTgsKy7K6Cwsedj15CJmkes1sT2dM0sL8e9POgOBlTwWP915RXxHylsGaAVMftuvDw2GKaw6gq7IG1j8jKwa9bJSW_XOyAuih0VzqM_Iq5y0ACGD8JTljPSgOmq_Ij6vJxx2WFGLwdC6YwoTU2clh-kivQy5xb8vPOMaH4OxIU8iPdLCuxJRpHOgYF9VOnvrqtVOhCd2cEtaC1-TFYMeMb07znHz_cnV_ed3cfvt6c3lx27i206XhyiuutBPSd952IDV02EkuXC_bTSdAWtV6QOe6oVdeetRWIiBvN63lHRPn5P2xd5_irxlzMbuQHY6jnTDO2SilRSXRV6M4Gl2KOScczD6FnU0Hw8AsTM3W_GVqFqaLWJnW1LtT_bzZof-XOUGshk9HA9YjfwdMJruwAPChwijGx_DEgs__5d0YpgX3Ix4wb-OcpsrPMJO5AXO3vHX5Kuha0jMh_gD6P57-</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Fujimoto, Toshio</creator><creator>Nanjyo, Hiroshi</creator><creator>Fukuda, Jun</creator><creator>Nakamura, Akira</creator><creator>Mizunuma, Hideki</creator><creator>Yaegashi, Nobuo</creator><creator>Sugiyama, Toru</creator><creator>Kurachi, Hirohisa</creator><creator>Sato, Akira</creator><creator>Tanaka, Toshinobu</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</title><author>Fujimoto, Toshio ; Nanjyo, Hiroshi ; Fukuda, Jun ; Nakamura, Akira ; Mizunuma, Hideki ; Yaegashi, Nobuo ; Sugiyama, Toru ; Kurachi, Hirohisa ; Sato, Akira ; Tanaka, Toshinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-26d6268c35d7da705807e7523c954b7305a64d0ecc7f96d5de8a5e0e24b4a2713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Architectural grade</topic><topic>Carcinoma, Endometrioid - drug therapy</topic><topic>Carcinoma, Endometrioid - pathology</topic><topic>Carcinoma, Endometrioid - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Distant recurrence</topic><topic>Endometrioid uterine cancer</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Local recurrence</topic><topic>Lymph Node Excision</topic><topic>Lymphatic Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Pelvic lymph node metastasis</topic><topic>Risk Factors</topic><topic>Uterine Neoplasms - drug therapy</topic><topic>Uterine Neoplasms - pathology</topic><topic>Uterine Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujimoto, Toshio</creatorcontrib><creatorcontrib>Nanjyo, Hiroshi</creatorcontrib><creatorcontrib>Fukuda, Jun</creatorcontrib><creatorcontrib>Nakamura, Akira</creatorcontrib><creatorcontrib>Mizunuma, Hideki</creatorcontrib><creatorcontrib>Yaegashi, Nobuo</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Kurachi, Hirohisa</creatorcontrib><creatorcontrib>Sato, Akira</creatorcontrib><creatorcontrib>Tanaka, Toshinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujimoto, Toshio</au><au>Nanjyo, Hiroshi</au><au>Fukuda, Jun</au><au>Nakamura, Akira</au><au>Mizunuma, Hideki</au><au>Yaegashi, Nobuo</au><au>Sugiyama, Toru</au><au>Kurachi, Hirohisa</au><au>Sato, Akira</au><au>Tanaka, Toshinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>112</volume><issue>2</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objectives To determine the relationship between histopathological prognostic factors and sites of initial recurrence in endometrioid uterine cancer. Methods A total of 355 patients (Stage I, n = 227; II, n = 38; III, n = 90) underwent primary radical surgery including complete systematic pelvic lymph node (PLN) and para-aortic lymph node (PALN) adenectomy followed by adjuvant chemotherapy who were at risk for recurrence. Relapse-free survival (RFS) and disease-related survival (DRS) were analyzed using the log-rank testing. Multivariate Cox regression analysis and logistic regression analysis were used to determine and estimate independent prognostic factors. Results Lymph-vascular space invasion (LVSI), architectural grade (AG), myometrial invasion, and PLN metastasis (PLNM) were identified as independent prognostic factors for RFS. AG ( p = 0.0043) related with local recurrence. Among patients who received adjuvant chemotherapy, patients with G3 tumor had higher ratio of recurrence (16/45) compared with G1/2 tumor (11/102) ( p = 0.0004). Meanwhile, PLNM related with distant recurrence ( p = 0.0008). There was a statistically significant difference in RFS according to the number of positive PLN sites (group 0: n = 313, 1: n = 16, ≥ 2: n = 26), five-year RFS in each group was 91.9%, 81.3%, and 41.2%, respectively. Conclusions Sites of initial recurrence were related with AG and PLNM in patients with endometrioid uterine cancer. Current chemotherapy alone may not be an effective adjuvant therapy to prevent recurrence in patients with G3 tumor and ≥ 2 positive PLN sites. Prospective clinical trial needs to be conducted to establish the strategy of adjuvant therapy with these patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19062082</pmid><doi>10.1016/j.ygyno.2008.10.019</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2009-02, Vol.112 (2), p.342-347
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_66830909
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adjuvant chemotherapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Architectural grade
Carcinoma, Endometrioid - drug therapy
Carcinoma, Endometrioid - pathology
Carcinoma, Endometrioid - surgery
Chemotherapy, Adjuvant
Disease-Free Survival
Distant recurrence
Endometrioid uterine cancer
Female
Hematology, Oncology and Palliative Medicine
Humans
Local recurrence
Lymph Node Excision
Lymphatic Metastasis
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Obstetrics and Gynecology
Pelvic lymph node metastasis
Risk Factors
Uterine Neoplasms - drug therapy
Uterine Neoplasms - pathology
Uterine Neoplasms - surgery
title Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endometrioid%20uterine%20cancer:%20Histopathological%20risk%20factors%20of%20local%20and%20distant%20recurrence&rft.jtitle=Gynecologic%20oncology&rft.au=Fujimoto,%20Toshio&rft.date=2009-02-01&rft.volume=112&rft.issue=2&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2008.10.019&rft_dat=%3Cproquest_cross%3E66830909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66830909&rft_id=info:pmid/19062082&rft_els_id=1_s2_0_S0090825808008913&rfr_iscdi=true